Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 26, 2007

Avalon Pharmaceuticals Initiates Primary Screening Phase in Novartis Collaboration

  • Avalon Pharmaceuticals initiated the primary screening phase under its drug discovery collaboration with Novartis. The collaboration aims to discover small molecule therapeutic compounds targeted against a pathway selected by Novartis. The terms of the collaboration provide for upfront, research-support, and milestone payments.

    Avalon is using its AvalonRx® drug discovery platform to screen, identify, and characterize compounds from the Novartis  proprietary compound library. Following Avalon's successful identification of a screen signature by monitoring large-scale gene expression changes resulting from disrupting the selected pathway, the parties have agreed to initiate the primary screen against a large subset of Novartis' compound library. Under the terms of the agreement, the initiation of the screening phase triggers a $500,000 payment to Avalon for research support.

  • You’re all set! Thank you for subscribing to GEN Highlights.